menu
    • menu

    Company profile for Sydnexis

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sydnexis Inc., is a privately held clinical stage biopharmaceutical company based in San Diego that is developing a proprietary formulation for decreasing myopic progression in children. Sydnexis recently initiated a Phase 3 study testing its patented eyedrop formulation, SYD-101.ydnexis was founded in San Diego in 2014 with the goal of developing a proprietary, stable, topical eyedrop to treat the progression of myopia in chi...
    Sydnexis Inc., is a privately held clinical stage biopharmaceutical company based in San Diego that is developing a proprietary formulation for decreasing myopic progression in children. Sydnexis recently initiated a Phase 3 study testing its patented eyedrop formulation, SYD-101.ydnexis was founded in San Diego in 2014 with the goal of developing a proprietary, stable, topical eyedrop to treat the progression of myopia in children.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SydnexisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    445 Marine View Avenue, Suite 295 Del Mar, Ca 92014
    Telephone
    Telephone
    858-925-6172
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://sydnexis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sydnexis To Unveil Phase 3 STAR Trial Data On SYD-101 At ARVO
    Sydnexis To Unveil Phase 3 STAR Trial Data On SYD-101 At ARVO

    02 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-01/sydnexis-to-present-new-data-from-phase-3-star-trial-of-syd-101-at-arvo-2026-annual-meeting

    PHARMIWEB
    02 May 2026
    Share Share
    Sydnexis Presents SYD-101 Phase 3 Data at 2026 AAPOS Meeting
    Sydnexis Presents SYD-101 Phase 3 Data at 2026 AAPOS Meeting

    23 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-23/sydnexis-announces-new-data-from-phase-3-star-trial-of-syd-101-presented-at-2026-aapos-annual-meetin

    PHARMIWEB
    23 Mar 2026
    Share Share
    UK Approves Santen's Ryjunea for Slowing Childhood Myopia
    UK Approves Santen's Ryjunea for Slowing Childhood Myopia

    06 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251106357538/en/Sydnexis-Announces-UK-Approval-of-Ryjunea-by-Partner-Santen-to-Slow-Progression-of-Childhood-Myopia

    BUSINESS WIRE
    06 Nov 2025
    Share Share
    Sydnexis Gets FDA CRL On SYD-101 For Pediatric Myopia
    Sydnexis Gets FDA CRL On SYD-101 For Pediatric Myopia

    23 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251023759236/en/Sydnexis-Receives-Complete-Response-Letter-from-FDA-for-SYD-101-to-Slow-Pediatric-Myopia-Progression

    BUSINESSWIRE
    23 Oct 2025
    Share Share
    Sydnexis gets EU approval for SYD-101 to slow Pediatric Myopia
    Sydnexis gets EU approval for SYD-101 to slow Pediatric Myopia

    05 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250605515551/en/Sydnexis-Announces-European-Commission-Approval-of-SYD-101-the-First-and-Only-Pharmaceutical-Treatment-for-Slowing-the-Progression-of-Pediatric-Myopia

    BUSINESSWIRE
    05 Jun 2025
    Share Share
    Sydnexis to Present Three Abstracts at ARVO 2025 Annual Meeting
    Sydnexis to Present Three Abstracts at ARVO 2025 Annual Meeting

    01 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250501030361/en/Sydnexis-Announces-Three-Abstracts-Accepted-for-Poster-Presentations-at-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-2025-Annual-Meeting

    BUSINESSWIRE
    01 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search